NCT02761187 · OUTCOME

Number of Participants Receiving Different Treatment Combinations

An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants · Source last updated 2025-02-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Baseline up to 5 years

Analysis population: All Enrolled Population included all participants who signed the inform consent form. Participants were reported more than once in each line of therapy. Data is reported only for 1st, 2nd 3rd and 4th line of therapy. The overall number of participants analyzed is the number of participants available for analyses.

Groups in this outcome

1st Line of Therapy

The most common treatment regimens prescribed in participants treated in 1st line of therapy were PI+IMiD, PI+AA, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).

2nd Line of Therapy

The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).

3rd Line of Therapy

The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).

4th Line of Therapy

The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
1st Line of Therapy	2195
2nd Line of Therapy	1685
3rd Line of Therapy	1279
4th Line of Therapy	845

Reported measurements

Bortezomib and Lenalidomide (VR)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	560	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	86	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	19	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	10	Not reported	Not reported	Not reported	Not reported

Bortezomib and Cyclophosphamide (VC)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	497	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	99	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	43	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	18	Not reported	Not reported	Not reported	Not reported

Bortezomib and Thalidomide (VT)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	272	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	60	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	10	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	11	Not reported	Not reported	Not reported	Not reported

Bortezomib and Melphalan (VM)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	75	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	16	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	8	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	3	Not reported	Not reported	Not reported	Not reported

Lenalidomide (R)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	21	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	39	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	22	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	5	Not reported	Not reported	Not reported	Not reported

Lenalidomide and Dexamethasone (RD)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	86	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	218	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	126	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	30	Not reported	Not reported	Not reported	Not reported

Cyclophosphamide and Thalidomide (CT)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	60	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	37	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	11	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	5	Not reported	Not reported	Not reported	Not reported

Melphalan and Thalidomide (MT)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	10	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	3	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	4	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	3	Not reported	Not reported	Not reported	Not reported

Thalidomide and Dexamethasone (TD)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	7	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	1	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	5	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	2	Not reported	Not reported	Not reported	Not reported

Bortezomib and dexamethasone (VD)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	95	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	47	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	18	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	6	Not reported	Not reported	Not reported	Not reported

Ixazomib and Lenalidomide (IR)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	4	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	96	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	115	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	34	Not reported	Not reported	Not reported	Not reported

Carfilzomib and Lenalidomide (KR)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	63	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	112	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	42	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	18	Not reported	Not reported	Not reported	Not reported

Bortezomib and Pomalidomide (VPom)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	0	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	7	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	2	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	6	Not reported	Not reported	Not reported	Not reported

Carfilzomib and Pomalidomide (KPom)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	1	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	27	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	22	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	12	Not reported	Not reported	Not reported	Not reported

Carfilzomib and dexamethasone (KD)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	3	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	59	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	76	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	46	Not reported	Not reported	Not reported	Not reported

Daratumumab-Bortezomib (dara-V)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	7	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	110	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	78	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	46	Not reported	Not reported	Not reported	Not reported

Daratumumab-Ixazomib (dara-I)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	1	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	12	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	7	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	3	Not reported	Not reported	Not reported	Not reported

Daratumumab-Lenalidomide (dara-R)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	3	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	149	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	70	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	31	Not reported	Not reported	Not reported	Not reported

Daratumumab-Pomalidomide (dara-Pom)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	0	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	49	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	72	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	43	Not reported	Not reported	Not reported	Not reported

Ixazomib and Dexamethasone (ID)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	1	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	14	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	13	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	9	Not reported	Not reported	Not reported	Not reported

Ixazomib (I)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	0	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	6	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	5	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	4	Not reported	Not reported	Not reported	Not reported

Pomalidomide and Dexamethasone (PomD)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	0	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	12	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	66	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	39	Not reported	Not reported	Not reported	Not reported

Daratumumab (Dara)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	0	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	15	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	21	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	56	Not reported	Not reported	Not reported	Not reported

Elotuzumab and Lenalidomide (Elo-R)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	7	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	42	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	20	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	10	Not reported	Not reported	Not reported	Not reported

Elotuzumab-Pomalidomide (Elo-Pom)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	0	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	6	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	10	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	14	Not reported	Not reported	Not reported	Not reported

Elotuzumab-Other Regimen (Elo-Other)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	6	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	4	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	4	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	1	Not reported	Not reported	Not reported	Not reported

Other Regimen

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	416	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	359	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	390	Not reported	Not reported	Not reported	Not reported
4th Line of Therapy	380	Not reported	Not reported	Not reported	Not reported

Complete source fields

calculate Pct

false

classes

categories
measurements
group Id
OG000
value
560
group Id
OG001
value
86
group Id
OG002
value
19
group Id
OG003
value
10
title
Bortezomib and Lenalidomide (VR)
categories
measurements
group Id
OG000
value
497
group Id
OG001
value
99
group Id
OG002
value
43
group Id
OG003
value
18
title
Bortezomib and Cyclophosphamide (VC)
categories
measurements
group Id
OG000
value
272
group Id
OG001
value
60
group Id
OG002
value
10
group Id
OG003
value
11
title
Bortezomib and Thalidomide (VT)
categories
measurements
group Id
OG000
value
75
group Id
OG001
value
16
group Id
OG002
value
8
group Id
OG003
value
3
title
Bortezomib and Melphalan (VM)
categories
measurements
group Id
OG000
value
21
group Id
OG001
value
39
group Id
OG002
value
22
group Id
OG003
value
5
title
Lenalidomide (R)
categories
measurements
group Id
OG000
value
86
group Id
OG001
value
218
group Id
OG002
value
126
group Id
OG003
value
30
title
Lenalidomide and Dexamethasone (RD)
categories
measurements
group Id
OG000
value
60
group Id
OG001
value
37
group Id
OG002
value
11
group Id
OG003
value
5
title
Cyclophosphamide and Thalidomide (CT)
categories
measurements
group Id
OG000
value
10
group Id
OG001
value
3
group Id
OG002
value
4
group Id
OG003
value
3
title
Melphalan and Thalidomide (MT)
categories
measurements
group Id
OG000
value
7
group Id
OG001
value
1
group Id
OG002
value
5
group Id
OG003
value
2
title
Thalidomide and Dexamethasone (TD)
categories
measurements
group Id
OG000
value
95
group Id
OG001
value
47
group Id
OG002
value
18
group Id
OG003
value
6
title
Bortezomib and dexamethasone (VD)
categories
measurements
group Id
OG000
value
4
group Id
OG001
value
96
group Id
OG002
value
115
group Id
OG003
value
34
title
Ixazomib and Lenalidomide (IR)
categories
measurements
group Id
OG000
value
63
group Id
OG001
value
112
group Id
OG002
value
42
group Id
OG003
value
18
title
Carfilzomib and Lenalidomide (KR)

denoms

counts
group Id
OG000
value
2195
group Id
OG001
value
1685
group Id
OG002
value
1279
group Id
OG003
value
845
units
Participants

groups

description
The most common treatment regimens prescribed in participants treated in 1st line of therapy were PI+IMiD, PI+AA, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
id
OG000
title
1st Line of Therapy
description
The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
id
OG001
title
2nd Line of Therapy
description
The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
id
OG002
title
3rd Line of Therapy
description
The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
id
OG003
title
4th Line of Therapy

param Type

COUNT_OF_PARTICIPANTS

population Description

All Enrolled Population included all participants who signed the inform consent form. Participants were reported more than once in each line of therapy. Data is reported only for 1st, 2nd 3rd and 4th line of therapy. The overall number of participants analyzed is the number of participants available for analyses.

reporting Status

POSTED

time Frame

Baseline up to 5 years

title

Number of Participants Receiving Different Treatment Combinations

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice